In breast cancer, for example, an estimated discrepancy as high as 19% is reported for estrogen receptor (ER) estimation by central or peripheral laboratories, when using different antibody clones, or when following various tissue-processing protocols.12,13,14,15,16 Automated digital methods could eliminate some of these problems and improve diagnostic accuracy and patient care. This evidence concerns the gene ESR1 and breast cancer.